Last Update: May 22, 2026
Non-interventional Study on the Use of ILARIS® (Canakinumab) Among Familial Mediterranean Fever and Still's Disease Patients Across Europe and Israel
ClinicalTrials.gov Identifier:
NCT07517250
Novartis Reference Number:CACZ885G2005
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.

Familial Mediterranean Fever, Still Disease, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still Disease
Recruiting
160
Mar 15, 2026
Mar 03, 2027
All
1 Year - (Child, Adult, Older Adult)

Eligibility Criteria

Inclusion criteria:

* Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD).
* Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment.

Exclusion criteria:

• Patients Aged \<2 Years (24 Months) at Index Date.

Novartis

Recruiting

Basel,Ch-4056,Switzerland

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

+41613241111